AB0834 DEVELOPMENT OF A CONCEPTUAL FRAMEWORK FOR A PATIENT REPORTED OUTCOME MEASURE TO CAPTURE PATIENTS’ PERCEPTIONS OF GLUCOCORTICOID THERAPY DURING TREATMENT FOR RHEUMATIC DISEASES

Background: Glucocorticoids (GCs) are a key treatment for the autoimmune rheumatic diseases; however, they produce numerous physical and psychological side effects. 1 The Outcome Measures in Rheumatology (OMERACT) Glucocorticoid Working Group have identified that there no Patient Reported (PROMs) assessing impact of systemic GC therapy across multiple diseases from patient’s perspective. 2,3 Objectives: aim is to explore GCs on symptoms health-related quality life adults with inflammatory diseases, inform items inclusion PROM. Key considerations will include patient perceptions at diagnosis over course treatment, use future randomised controlled trials or clinical practice. Methods: An international steering committee comprising researchers, rheumatology clinicians, methodologists partners UK, Australia USA developed an initial conceptual framework informed by review literature. Semi-structured interviews were conducted each country patients who had disease received therapy. explored salient aspects associated being treated GCs. Results: Interviews been completed three continents range demographic features, rheumatological conditions duration dosage Figure shows developing PROM (Steroid PRO). 1. Conclusion: This act as evolving guide development patients’ perspectives glucocorticoid Future work inductive analysis qualitative transcripts candidate questionnaire items, cognitive interviewing, linguistic translatability assessment, validation survey define final its measurement properties. References: [1]Cheah JTL, Robson JC, Black RJ, et al . perspective adverse effects use: A systematic quantitative studies. From OMERACT working group. Semin Arthritis Rheum. 2020 Oct; 50 (5):996-1005. [2]Black Goodman SM, al. Patient-reported Measure Effect Therapy Adults Inflammatory Diseases Is Needed: Report 2016 Special Interest Group. J Rheumatol. 2017; 44 (11):1754-8. [3]Cheah Toward Core Domain Set Impact Rheumatic Diseases: 2018 2019; 46 (9):1179-1182. Disclosure Interests: Susan Bridgewater Grant/research support from: Grant Vifor Pharma independent investigator-led study develop PRO steroids, Jill Dawson: None declared, Mwidimi Ndosi: Rachel Black: Jonathan T.L. Cheah: Emma Dures: Nilasha Ghosh: Elizabeth Hoon: Iris Navarro-Millan Consultant of: Received consultant fees SOBI, Diyu Pearce-Fisher: Pamela Richards: Carlee Ruediger: Christine Silverthorne: Joanna Tieu Pharma, Sarah Mackie Consultancy behalf institution Roche/Chugai, Sanofi, AbbVie AstraZeneca, Educational grant Roche attend EULAR2019, Goodman: Catherine Hill: Speakers bureau: educational webinar, steroids